consolidated financial statements of the Company for the year ended 31 December 2017, which is equal to 15 percent or higher, but less than 50 percent, this is considered as a Type 2 transaction pursuant to the
of this products of the company to decrease. However, the company has increased online distribution channels as a choice for new generation customers. It is expected that the domestic market will
Ended December 31, 2018 To The President The Stock Exchange of Thailand Management Discussion and Analysis Consolidated Financial Statements For Financial Year ended December 31, 2018 Overall Group
, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00
Limited ( “ the Company” ) would like to submit this Management Discussion and Analysis for the year ended 31 December 2019 with details as follows: ( Since the consolidated financial statements included
relation to import duty assessment. งบกาํไรขาดทุนเบ็ดเสร็จ Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04
relation to import duty assessment. Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04) (39.77) Selling expenses
Limited (“the Company”) would like to clarify the consolidated financial statements of the Company for the 2nd quarter of fiscal year 2017 ended as of June 30, 2017, which can be summarized as follows
increase of minimum wages and the employment due to the branch expansion, as well as the increase of the rents of the existing branches and new branches. Net Profit In the Quarter 2 of 2017, the Company and
of the staff cost resulting from the increase of minimum wages and the employment due to the branch expansion, as well as the increase of the rents of the existing branches and new branches. Net Profit